Summary:

In this presentation, Dr. Rebecca Riggins presents new findings on how anti-HER2 therapy reshapes estrogen receptor (ER) activity in triple-positive breast cancer. Using high-resolution chromatin mapping, her team reveals that trastuzumab and pertuzumab treatment drives nuclear HER2 localization, expands ER chromatin binding, and activates WNT and RAGE pathway genes—mechanisms linked to poor clinical outcomes. These insights highlight the complexity of receptor crosstalk and the need for integrated therapeutic strategies.

Topics to be covered:

  • Nuclear HER2 signaling and its role in resistance to anti-HER2 therapy in triple-positive breast cancer
  • Estrogen receptor reprogramming and chromatin remodeling following trastuzumab/pertuzumab treatment
  • Identification of WNT and RAGE pathway gene activation linked to poor outcomes in HER2-positive breast cancer

Speakers:

Rebecca B. Riggins, PhD Associate Professor of Oncology,  Georgetown Lombardi Comprehensive Cancer Center Rebecca B. Riggins, PhD
Associate Professor of Oncology,
Georgetown Lombardi Comprehensive Cancer Center

Browse Our Webinar Library